{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:45:52Z","timestamp":1761659152228,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ajg.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T10:06:12Z","timestamp":1605866772000},"page":"23-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study"],"prefix":"10.1016","volume":"22","author":[{"given":"Ik Sung","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Goon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2020.09.001_b0005","article-title":"The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C","volume":"2018","author":"Younossi","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.ajg.2020.09.001_b0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/liv.12108","article-title":"A nationwide seroepidemiology of hepatitis C virus infection in South Korea","volume":"33","author":"Kim","year":"2013","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.ajg.2020.09.001_b0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2012.18.2.219","article-title":"Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience","volume":"18","author":"Cho","year":"2012","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ajg.2020.09.001_b0020","doi-asserted-by":"crossref","unstructured":"Mun Hyuk Seong, Byung Hak K, Sook-Hyang Jeong D. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. Mun. J Med Virol. 2013;85:1724\u201333.","DOI":"10.1002\/jmv.23661"},{"issue":"1\u20132","key":"10.1016\/j.ajg.2020.09.001_b0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000087266","article-title":"Current status of hepatitis C virus infection in Korea","volume":"49","author":"Jeong","year":"2006","journal-title":"Intervirology"},{"issue":"21","key":"10.1016\/j.ajg.2020.09.001_b0030","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and Ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2020.09.001_b0035","doi-asserted-by":"crossref","unstructured":"The Korean Association for the Study of the L. KASL clinical practice guidelines: Management of hepatitis C. Clinical and Molecular Hepatology. 2016;22(1):76\u2013139.","DOI":"10.3350\/cmh.2016.22.1.76"},{"issue":"2","key":"10.1016\/j.ajg.2020.09.001_b0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ajg.2020.09.001_b0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Chung","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ajg.2020.09.001_b0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/jvh.12499","article-title":"A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus","volume":"23","author":"Ahn","year":"2016","journal-title":"J Viral Hepatitis"},{"key":"10.1016\/j.ajg.2020.09.001_b0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3350\/cmh.2017.0070","article-title":"Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: a retrospective multi-institutional study","author":"Kim","year":"2018","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.ajg.2020.09.001_b0060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.12.002","article-title":"Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience","volume":"66","author":"Mangia","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2020.09.001_b0065","doi-asserted-by":"crossref","unstructured":"Korean Association for the Study of the L. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22(1):76\u2013139.","DOI":"10.3350\/cmh.2016.22.1.76"},{"issue":"9","key":"10.1016\/j.ajg.2020.09.001_b0070","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ajg.2020.09.001_b0075","doi-asserted-by":"crossref","unstructured":"Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Ratziu V, Ding X, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir- containing regimens for hepatitis C Virus. 2014:41\u201345.","DOI":"10.1002\/hep.27366"},{"issue":"2","key":"10.1016\/j.ajg.2020.09.001_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.379","article-title":"Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort","volume":"6","author":"Benhammou","year":"2018","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"10.1016\/j.ajg.2020.09.001_b0085","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int."},{"issue":"8","key":"10.1016\/j.ajg.2020.09.001_b0090","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/cid\/cir991","article-title":"Transmission of hepatitis C virus infection through tattooing and piercing: a critical review","volume":"54","author":"Tohme","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajg.2020.09.001_b0095","doi-asserted-by":"crossref","unstructured":"Kim BK, Jang ES, Kim JH, Park SY, Ahn SV, Kim HJ, et al. Current status of and strategies for hepatitis C control in South Korea. Clin Mol Hepatol. 2017;23(3):212\u2013128.","DOI":"10.3350\/cmh.2017.0105"},{"issue":"3","key":"10.1016\/j.ajg.2020.09.001_b0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cld.2017.03.004","article-title":"Metabolic manifestations of hepatitis C virus: diabetes mellitus","volume":"21","author":"Serfaty","year":"2017","journal-title":"Dyslipidemia Clin Liver Dis."},{"key":"10.1016\/j.ajg.2020.09.001_b0105","first-page":"1","article-title":"Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents","author":"Gualerzi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajg.2020.09.001_b0110","article-title":"HCV infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure","volume":"0\u20132","author":"Lim","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"SUPPL. 1","key":"10.1016\/j.ajg.2020.09.001_b0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1590-8658(07)80012-0","article-title":"HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques","volume":"39","author":"Boddi","year":"2007","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.ajg.2020.09.001_b0120","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijcard.2018.04.058","article-title":"Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function","volume":"271","author":"Schmidt","year":"2018","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ajg.2020.09.001_b0125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40121-017-0171-0","article-title":"Effect of hepatitis C treatment with ombitasvir\/paritaprevir\/R + dasabuvir on renal, cardiovascular and metabolic extrahepatic manifestations: a post-hoc analysis of phase 3 clinical trials","volume":"6","author":"Mehta","year":"2017","journal-title":"Infect Dis Therapy"},{"issue":"3","key":"10.1016\/j.ajg.2020.09.001_b0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J Viral Hepat"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197920301064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197920301064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:41:45Z","timestamp":1761658905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197920301064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1687197920301064"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2020.09.001","relation":{},"ISSN":["1687-1979"],"issn-type":[{"type":"print","value":"1687-1979"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}